Exhibit 99.1
[VIROLOGIC LOGO]
FOR IMMEDIATE RELEASE                           CONTACT:
MARCH 26, 2002                                  Karen Wilson, CFO
                                                (650) 624-4164
                                                kwilson@virologic.com
                                                www.virologic.com

        VIROLOGIC RAISES $10 MILLION THROUGH PRIVATE PLACEMENT

     -- Cash Position Sufficient to Achieve Breakeven by the End of 2002--

SOUTH SAN FRANCISCO, CA -- ViroLogic, Inc. (NASDAQ: VLGC) today announced it has
closed a transaction to sell newly designated shares of 6% convertible preferred
stock to several large investors in a private placement resulting in gross
proceeds to the company of $10 million.

ViroLogic expects to use the proceeds from this financing to support and enhance
ongoing commercial activities, accelerate research and development of new
products, and for general administrative expenses, capital expenditures and
working capital.

"The Company's cash position should now be sufficient to get us to breakeven by
the end of 2002," said Bill Young, ViroLogic's Chairman and CEO. "It comes at a
great time as we continue to increase sales, launch new products and turn the
corner to profitability."

ViroLogic develops and markets rapid, highly sensitive drug resistance assays
that allow physicians to directly and reliably measure the level of clinically
significant HIV drug resistance. With this information, physicians can
individualize treatment regimens for their patients to maintain effective
therapy and avoid unnecessary side effects, resulting in improved outcomes and
reduced treatment costs. Pharmaceutical companies are also using ViroLogic's
assays to develop new drugs to which HIV might be less resistant. ViroLogic is
the only company to directly market a full line of premium resistance
technologies, including phenotyping, genotyping and the combination of the two.
In addition, ViroLogic has a robust pipeline of new products which it plans to
launch throughout the year, including a patient testing assay for viral fitness
and drug development assays for HIV vaccines and hepatitis B virus.

The preferred stock will be convertible into common stock at a premium to the
current market price. The purchasers will also receive warrants to purchase a
total of 2.2 million shares of common stock, at an exercise price that is also
at a premium to the current market price. The offer and sale of the securities
being sold by ViroLogic in the private placement will not be and has not been
registered under the Securities Act of 1933, as amended, and may not be sold by
ViroLogic absent registration or an applicable exemption from registration
requirements. However, the Company has agreed to file a registration statement
for the resale of the shares underlying the preferred stock and the warrants.
This news release is not an offer to sell, or a solicitation of an offer to buy,
the securities discussed herein.




ABOUT VIROLOGIC

ViroLogic is a biotechnology company advancing individualized medicine and
pharmacogenomics by discovering, developing and marketing innovative products to
guide and improve treatment of serious viral diseases such as AIDS and
hepatitis. The Company's products are designed to help doctors optimize
treatment regimens for their patients that lead to better outcomes and reduced
costs. The Company's technology is also being used by numerous biopharmaceutical
companies to develop new and improved antiviral therapeutics and vaccines
targeted at emerging drug-resistant viruses.

Certain statements in this press release are forward-looking, including
statements relating to the offer and sale of shares of preferred stock and the
issuance of warrants, the potential of the Company to reach breakeven and become
profitable, as well as anticipated uses of proceeds and potential pipeline and
product development efforts. These forward-looking statements are subject to
risks and uncertainties and other factors, which may cause actual results to
differ materially from the anticipated results or other expectations expressed
in such forward-looking statements. These risks and uncertainties include, but
are not limited to, whether planned pipeline and product development efforts
will be successful, whether PhenoSense(TM) testing will achieve market
acceptance, whether payers will authorize reimbursement for our products,
whether we will be able to expand our sales and marketing capabilities, whether
we encounter problems or delays in automating our process, whether we
successfully introduce new products using our PhenoSense technology, including
entry, fitness, vaccine and hepatitis assays, whether intellectual property
underlying our PhenoSense technology is adequate, whether we are able to build
brand loyalty, the ability to raise additional capital, and other risks and
uncertainties detailed from time to time in our reports to the Securities and
Exchange Commission, including our Annual Report on Form 10-K for the year ended
December 31, 2000 and the Company's most recent Report on Form 10-Q.

                                      # # #